{{Rsnum
|rsid=10892151
|Gene=DSCAML1
|Chromosome=11
|position=117661016
|Orientation=plus
|GMAF=0.08035
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=DSCAML1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 93.8 | 6.2 | 0.0
| HCB | 95.6 | 4.4 | 0.0
| JPT | 99.1 | 0.9 | 0.0
| YRI | 35.4 | 52.4 | 12.2
| ASW | 57.9 | 35.1 | 7.0
| CHB | 95.6 | 4.4 | 0.0
| CHD | 96.3 | 3.7 | 0.0
| GIH | 88.1 | 11.9 | 0.0
| LWK | 71.8 | 26.4 | 1.8
| MEX | 94.8 | 5.2 | 0.0
| MKK | 79.5 | 19.9 | 0.6
| TSI | 94.1 | 5.9 | 0.0
| HapMapRevision=28
}}
{{PMID Auto GWAS
|PMID=19074352
|Trait=Triglycerides
|Title=A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection
|RiskAllele=A
|Pval=3E-29
|OR=NR
|ORtxt=NR
|OA=1
}}

{{omim
|desc=APOLIPOPROTEIN C-III; APOC3
|id=107720
|rsnum=10892151
}}

{{PharmGKB
|RSID=rs10892151
|Name_s=
|Gene_s=DSCAML1
|Feature=
|Evidence=PubMed ID:19074352; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. (Initial Sample Size: 809 individuals; Replication Sample Size: 698 individuals); (Region: 11q23.3; Reported Gene(s): APOA1, APOC3, APOA4, APOA5, DSCAML1; Risk Allele: rs10892151-A); (p-value= 3E-29).This variant is associated with Triglycerides.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740129
}}

{{PharmGKB
|RSID=rs10892151
|Name_s=
|Gene_s=DSCAML1
|Feature=
|Evidence=PubMed ID:19074352
|Annotation=In Amish individuals participating in the Heredity and Phenotype Intervention (HAPI) Heart Study, the A allele of this SNP was in strong linkage disequilibrium with a mutation in the APOC3 gene (C55T; R19X). This mutation was associated with lower fasting and postprandial triglyceride levels, as well as with reduced coronary artery calcification, suggesting a cardioprotective effect for carriers of this mutation.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162363740
}}

{{PMID Auto
|PMID=21939545
|Title=Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10892151
|overall_frequency_n=15
|overall_frequency_d=128
|overall_frequency=0.117188
|n_genomes=11
|n_genomes_annotated=0
|n_haplomes=12
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}